240 related articles for article (PubMed ID: 18724381)
1. Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs.
McPate MJ; Duncan RS; Hancox JC; Witchel HJ
Br J Pharmacol; 2008 Nov; 155(6):957-66. PubMed ID: 18724381
[TBL] [Abstract][Full Text] [Related]
2. Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome.
McPate MJ; Duncan RS; Witchel HJ; Hancox JC
J Mol Cell Cardiol; 2006 Sep; 41(3):563-6. PubMed ID: 16842817
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of the short QT N588K mutation at 37 degrees C on hERG K+ channel current during ventricular, Purkinje fibre and atrial action potentials: an action potential clamp study.
McPate MJ; Zhang H; Adeniran I; Cordeiro JM; Witchel HJ; Hancox JC
J Physiol Pharmacol; 2009 Mar; 60(1):23-41. PubMed ID: 19439805
[TBL] [Abstract][Full Text] [Related]
4. Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel.
El Harchi A; Melgari D; Zhang YH; Zhang H; Hancox JC
PLoS One; 2012; 7(12):e52451. PubMed ID: 23300672
[TBL] [Abstract][Full Text] [Related]
5. The N588K-HERG K+ channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37 degrees C.
McPate MJ; Duncan RS; Milnes JT; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2005 Aug; 334(2):441-9. PubMed ID: 16011830
[TBL] [Abstract][Full Text] [Related]
6. A novel mutation in the KCNH2 gene associated with short QT syndrome.
Sun Y; Quan XQ; Fromme S; Cox RH; Zhang P; Zhang L; Guo D; Guo J; Patel C; Kowey PR; Yan GX
J Mol Cell Cardiol; 2011 Mar; 50(3):433-41. PubMed ID: 21130771
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of the β-adrenoceptor blockers carvedilol and metoprolol on SQT1- and SQT2-mutant channels.
Bodi I; Franke G; Pantulu ND; Wu K; Perez-Feliz S; Bode C; Zehender M; zur Hausen A; Brunner M; Odening KE
J Cardiovasc Electrophysiol; 2013 Oct; 24(10):1163-71. PubMed ID: 23718892
[TBL] [Abstract][Full Text] [Related]
8. Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels.
Perrin MJ; Kuchel PW; Campbell TJ; Vandenberg JI
Mol Pharmacol; 2008 Nov; 74(5):1443-52. PubMed ID: 18701618
[TBL] [Abstract][Full Text] [Related]
9. Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.
Du C; Zhang Y; El Harchi A; Dempsey CE; Hancox JC
J Mol Cell Cardiol; 2014 Sep; 74(100):220-30. PubMed ID: 24877995
[TBL] [Abstract][Full Text] [Related]
10. In vivo effects of mutant HERG K+ channel inhibition by disopyramide in patients with a short QT-1 syndrome: a pilot study.
Schimpf R; Veltmann C; Giustetto C; Gaita F; Borggrefe M; Wolpert C
J Cardiovasc Electrophysiol; 2007 Nov; 18(11):1157-60. PubMed ID: 17711440
[TBL] [Abstract][Full Text] [Related]
11. Modulation of I(Kr) inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome.
Cordeiro JM; Brugada R; Wu YS; Hong K; Dumaine R
Cardiovasc Res; 2005 Aug; 67(3):498-509. PubMed ID: 16039272
[TBL] [Abstract][Full Text] [Related]
12.
Whittaker DG; Hancox JC; Zhang H
Front Physiol; 2018; 9():1888. PubMed ID: 30687112
[TBL] [Abstract][Full Text] [Related]
13. hERG1a/1b heteromeric currents exhibit amplified attenuation of inactivation in variant 1 short QT syndrome.
McPate MJ; Zhang H; Cordeiro JM; Dempsey CE; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2009 Aug; 386(1):111-7. PubMed ID: 19501051
[TBL] [Abstract][Full Text] [Related]
14. In silico assessment of the effects of quinidine, disopyramide and E-4031 on short QT syndrome variant 1 in the human ventricles.
Luo C; Wang K; Zhang H
PLoS One; 2017; 12(6):e0179515. PubMed ID: 28632743
[TBL] [Abstract][Full Text] [Related]
15. Action potential clamp characterization of the S631A hERG mutation associated with short QT syndrome.
Butler A; Zhang Y; Stuart AG; Dempsey CE; Hancox JC
Physiol Rep; 2018 Sep; 6(17):e13845. PubMed ID: 30175559
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide.
Paul AA; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2001 Feb; 280(5):1243-50. PubMed ID: 11162661
[TBL] [Abstract][Full Text] [Related]
17. Characterisation of recombinant HERG K+ channel blockade by the Class Ia antiarrhythmic drug procainamide.
Ridley JM; Milnes JT; Benest AV; Masters JD; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2003 Jun; 306(2):388-93. PubMed ID: 12804575
[TBL] [Abstract][Full Text] [Related]
18. Biophysical characterization of the short QT mutation hERG-N588K reveals a mixed gain-and loss-of-function.
Grunnet M; Diness TG; Hansen RS; Olesen SP
Cell Physiol Biochem; 2008; 22(5-6):611-24. PubMed ID: 19088443
[TBL] [Abstract][Full Text] [Related]
19. The Susceptibilities of Human Ether-à-Go-Go-Related Gene Channel with the G487R Mutation to Arrhythmogenic Factors.
Hisajima N; Hata Y; Kinoshita K; Fukushima T; Nishida N; Kano M; Tabata T
Biol Pharm Bull; 2015; 38(5):781-4. PubMed ID: 25947924
[TBL] [Abstract][Full Text] [Related]
20. Probing the interaction between inactivation gating and Dd-sotalol block of HERG.
Numaguchi H; Mullins FM; Johnson JP; Johns DC; Po SS; Yang IC; Tomaselli GF; Balser JR
Circ Res; 2000 Nov; 87(11):1012-8. PubMed ID: 11090546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
